vs
Side-by-side financial comparison of Twist Bioscience Corp (TWST) and Via Renewables, Inc. (VIASP). Click either name above to swap in a different company.
Via Renewables, Inc. is the larger business by last-quarter revenue ($127.8M vs $103.7M, roughly 1.2× Twist Bioscience Corp). Via Renewables, Inc. runs the higher net margin — 5.4% vs -29.4%, a 34.8% gap on every dollar of revenue. On growth, Via Renewables, Inc. posted the faster year-over-year revenue change (22.5% vs 16.9%). Via Renewables, Inc. produced more free cash flow last quarter ($-4.8M vs $-34.8M).
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
EDF Power Solutions is a wholly owned subsidiary of the French utility EDF Group, specializing in renewable energy production. As an integrated operator, the Group develops and finances the construction of renewable energy facilities, and manages operations and maintenance for its own account and for third parties.
TWST vs VIASP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $103.7M | $127.8M |
| Net Profit | $-30.5M | $6.9M |
| Gross Margin | 52.0% | 34.4% |
| Operating Margin | -31.7% | 15.2% |
| Net Margin | -29.4% | 5.4% |
| Revenue YoY | 16.9% | 22.5% |
| Net Profit YoY | 3.4% | -30.9% |
| EPS (diluted) | $-0.50 | $1.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $103.7M | $127.8M | ||
| Q3 25 | — | $103.3M | ||
| Q2 25 | — | $90.0M | ||
| Q1 25 | — | $142.3M | ||
| Q4 24 | — | $104.3M | ||
| Q3 24 | — | $93.8M | ||
| Q2 24 | — | $86.7M | ||
| Q1 24 | — | $114.1M |
| Q4 25 | $-30.5M | $6.9M | ||
| Q3 25 | — | $757.0K | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | — | $8.8M | ||
| Q4 24 | — | $9.9M | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $7.6M | ||
| Q1 24 | — | $8.6M |
| Q4 25 | 52.0% | 34.4% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 30.0% | ||
| Q1 25 | — | 32.9% | ||
| Q4 24 | — | 51.9% | ||
| Q3 24 | — | 26.8% | ||
| Q2 24 | — | 50.4% | ||
| Q1 24 | — | 39.5% |
| Q4 25 | -31.7% | 15.2% | ||
| Q3 25 | — | 3.1% | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 17.5% | ||
| Q4 24 | — | 31.5% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | 23.8% | ||
| Q1 24 | — | 22.6% |
| Q4 25 | -29.4% | 5.4% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 3.0% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | — | 8.8% | ||
| Q1 24 | — | 7.5% |
| Q4 25 | $-0.50 | $1.19 | ||
| Q3 25 | — | $-0.41 | ||
| Q2 25 | — | $0.09 | ||
| Q1 25 | — | $1.83 | ||
| Q4 24 | — | $2.33 | ||
| Q3 24 | — | $-0.17 | ||
| Q2 24 | — | $1.51 | ||
| Q1 24 | — | $1.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $197.9M | $41.8M |
| Total DebtLower is stronger | — | $120.0M |
| Stockholders' EquityBook value | $456.1M | $67.7M |
| Total Assets | $638.1M | $331.3M |
| Debt / EquityLower = less leverage | — | 1.77× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $197.9M | $41.8M | ||
| Q3 25 | — | $53.6M | ||
| Q2 25 | — | $62.1M | ||
| Q1 25 | — | $64.7M | ||
| Q4 24 | — | $53.1M | ||
| Q3 24 | — | $66.6M | ||
| Q2 24 | — | $53.6M | ||
| Q1 24 | — | $50.4M |
| Q4 25 | — | $120.0M | ||
| Q3 25 | — | $105.0M | ||
| Q2 25 | — | $100.0M | ||
| Q1 25 | — | $101.0M | ||
| Q4 24 | — | $106.0M | ||
| Q3 24 | — | $89.0M | ||
| Q2 24 | — | $93.0M | ||
| Q1 24 | — | $91.0M |
| Q4 25 | $456.1M | $67.7M | ||
| Q3 25 | — | $63.7M | ||
| Q2 25 | — | $68.2M | ||
| Q1 25 | — | $72.7M | ||
| Q4 24 | — | $66.7M | ||
| Q3 24 | — | $58.2M | ||
| Q2 24 | — | $58.3M | ||
| Q1 24 | — | $53.2M |
| Q4 25 | $638.1M | $331.3M | ||
| Q3 25 | — | $304.8M | ||
| Q2 25 | — | $316.3M | ||
| Q1 25 | — | $347.4M | ||
| Q4 24 | — | $344.9M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $299.7M | ||
| Q1 24 | — | $302.7M |
| Q4 25 | — | 1.77× | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | — | 1.47× | ||
| Q1 25 | — | 1.39× | ||
| Q4 24 | — | 1.59× | ||
| Q3 24 | — | 1.53× | ||
| Q2 24 | — | 1.60× | ||
| Q1 24 | — | 1.71× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-24.8M | $-4.2M |
| Free Cash FlowOCF − Capex | $-34.8M | $-4.8M |
| FCF MarginFCF / Revenue | -33.5% | -3.7% |
| Capex IntensityCapex / Revenue | 9.6% | 0.4% |
| Cash ConversionOCF / Net Profit | — | -0.61× |
| TTM Free Cash FlowTrailing 4 quarters | — | $39.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-24.8M | $-4.2M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $19.0M | ||
| Q1 25 | — | $24.9M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | — | $20.1M | ||
| Q2 24 | — | $11.2M | ||
| Q1 24 | — | $17.1M |
| Q4 25 | $-34.8M | $-4.8M | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | — | $18.4M | ||
| Q1 25 | — | $23.5M | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $19.7M | ||
| Q2 24 | — | $10.9M | ||
| Q1 24 | — | $16.6M |
| Q4 25 | -33.5% | -3.7% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 20.5% | ||
| Q1 25 | — | 16.5% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | — | 21.0% | ||
| Q2 24 | — | 12.6% | ||
| Q1 24 | — | 14.6% |
| Q4 25 | 9.6% | 0.4% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | — | -0.61× | ||
| Q3 25 | — | 3.12× | ||
| Q2 25 | — | 6.94× | ||
| Q1 25 | — | 2.84× | ||
| Q4 24 | — | 0.20× | ||
| Q3 24 | — | 9.41× | ||
| Q2 24 | — | 1.47× | ||
| Q1 24 | — | 2.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
VIASP
| Retail Electricity | $79.7M | 62% |
| Retail Natural Gas | $48.9M | 38% |
